These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11300477)

  • 1. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis--implications for tumor tolerance.
    Robinson BW; Scott BM; Lake RA; Stumbles PA; Nelson DJ; Fisher S; Marzo AL
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):811s-817s. PubMed ID: 11300477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
    Marzo AL; Lake RA; Robinson BW; Scott B
    Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor antigens are constitutively presented in the draining lymph nodes.
    Marzo AL; Lake RA; Lo D; Sherman L; McWilliam A; Nelson D; Robinson BW; Scott B
    J Immunol; 1999 May; 162(10):5838-45. PubMed ID: 10229818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
    Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
    Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8alpha+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor.
    McDonnell AM; Prosser AC; van Bruggen I; Robinson BW; Currie AJ
    Eur J Immunol; 2010 Jun; 40(6):1617-27. PubMed ID: 20373290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells.
    Robson NC; Donachie AM; Mowat AM
    Eur J Immunol; 2008 May; 38(5):1238-46. PubMed ID: 18398931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors.
    Hermans IF; Daish A; Yang J; Ritchie DS; Ronchese F
    Cancer Res; 1998 Sep; 58(17):3909-17. PubMed ID: 9731502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
    Kim TS; Lee BC; Kim E; Cho D; Cohen EP
    Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vulnerability of allografts to rejection by MHC class II-restricted T-cell receptor transgenic mice.
    Lee MK; Huang X; Jarrett BP; Moore DJ; Desai NM; Moh Lian M; Markmann JW; Deng S; Frank A; Singer A; Velidedeoglu E; Caton AJ; Markmann AJ
    Transplantation; 2003 Apr; 75(8):1415-22. PubMed ID: 12717241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen.
    Bai XF; Gao JX; Liu J; Wen J; Zheng P; Liu Y
    Cancer Res; 2001 Sep; 61(18):6860-7. PubMed ID: 11559562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.
    Cuenca A; Cheng F; Wang H; Brayer J; Horna P; Gu L; Bien H; Borrello IM; Levitsky HI; Sotomayor EM
    Cancer Res; 2003 Dec; 63(24):9007-15. PubMed ID: 14695219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.
    Chung Y; Chang JH; Kim BS; Lee JM; Kim HY; Kang CY
    Eur J Immunol; 2007 Jun; 37(6):1453-62. PubMed ID: 17474148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
    Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery by Trypanosoma cruzi of proteins into the MHC class I antigen processing and presentation pathway.
    Garg N; Nunes MP; Tarleton RL
    J Immunol; 1997 Apr; 158(7):3293-302. PubMed ID: 9120286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.
    Murillo O; Dubrot J; Palazón A; Arina A; Azpilikueta A; Alfaro C; Solano S; Ochoa MC; Berasain C; Gabari I; Pérez-Gracia JL; Berraondo P; Hervás-Stubbs S; Melero I
    Eur J Immunol; 2009 Sep; 39(9):2424-36. PubMed ID: 19662633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide.
    Chung SW; Cohen EP; Kim TS
    Vaccine; 2004 Jun; 22(20):2547-57. PubMed ID: 15193380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.